Product Details

Uniprot No.

Target Names

Alternative Names

C358B7.1 antibody; p18 antibody; SUMO 1 protein ligase antibody; SUMO conjugating enzyme UBC9 antibody; SUMO-conjugating enzyme UBC9 antibody; SUMO-protein ligase antibody; SUMO1 protein ligase antibody; UBC9 antibody; UBC9_HUMAN antibody; UBCE9 antibody; Ube2i antibody; Ubiquitin carrier protein 9 antibody; Ubiquitin carrier protein antibody; Ubiquitin carrier protein I antibody; Ubiquitin conjugating enzyme 9 antibody; Ubiquitin conjugating enzyme E2I (homologous to yeast UBC9) antibody; Ubiquitin conjugating enzyme E2I (UBC9 homolog; yeast) antibody; Ubiquitin conjugating enzyme UbcE2A antibody; Ubiquitin like protein SUMO 1 conjugating enzyme antibody; Ubiquitin protein ligase E2I antibody; Ubiquitin-conjugating enzyme E2 I antibody; Ubiquitin-protein ligase I antibody

Species Reactivity

Human, Mouse

Immunogen

A synthesized peptide derived from human UBE2I

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

7C4

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, WB, FC

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:2000
FC	1:50-1:200

Protocols

ELISA Protocol
Western Blotting(WB) Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

UBE2I, also known as UBC9, serves as the sole E2-conjugating enzyme in the SUMOylation pathway, making it an essential regulator of protein function across virtually all cellular processes. This small ubiquitin-like modifier conjugating enzyme plays critical roles in DNA repair, transcriptional regulation, nuclear transport, and cell cycle progression. Given its central position in post-translational modification networks, UBE2I has emerged as a significant target in cancer biology, neurodegenerative disease research, and studies of cellular stress responses.

This recombinant monoclonal antibody, generated from clone 7C4 in rabbit host, offers the reproducibility and consistency that demanding experimental workflows require. Because the antibody sequence is defined and produced recombinantly, researchers can expect reliable performance across experiments and over time, eliminating the lot-to-lot variability that can complicate long-term studies or multi-site collaborations.

Validation testing demonstrates robust performance across multiple platforms. Western blot analysis confirms specific detection of UBE2I at the expected 18 kDa molecular weight across an extensive panel of human cell lines including A549, HeLa, HepG2, HEK293, K562, and SH-SY5Y, as well as mouse NIH/3T3 cells, supporting the antibody's cross-species reactivity with both human and mouse samples. Flow cytometry validation in Jurkat cells further demonstrates utility for single-cell analysis of intracellular UBE2I levels, expanding experimental possibilities beyond lysate-based approaches.

Whether investigating SUMOylation dynamics in cancer models, exploring protein quality control mechanisms, or characterizing post-translational modification networks, this antibody provides a dependable tool for advancing your research into this fundamental cellular pathway.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Target Background

Function

Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3, SUMO4 and SUMO1P1/SUMO5 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2, CBX4 and ZNF451. Can catalyze the formation of poly-SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Sumoylates p53/TP53 at 'Lys-386'. Mediates sumoylation of ERCC6 which is essential for its transcription-coupled nucleotide excision repair activity.

Gene References into Functions

Study demonstrated overexpression of Ubc9 protein in osteosarcoma. Silencing Ubc9 in osteosarcoma cell lines induced decoupling of SUMO1 from Cx43, generating increased free Cx43 levels, which is important for reconstructing gap junction intercellular communication and recovering cellular functions. PMID: 29956745
Data show that the forkhead Box Protein P3 (FOXP3) response element at the -310 bp region, but not the -2182 bp region, is mainly required for ubiquitin conjugating enzyme 9 (UBC9) activation by FOXP3. PMID: 30011797
Study provides an insight into the role of the RNF4 to balance the role of SUMO signaling by directly targeting Ubc9 and SUMO E3 ligases. PMID: 29180619
The SUMO1/UBC9 axis may regulate Nox1mediated diabetic retinopathy by inhibiting reactive oxygen species generation and apoptosis. PMID: 29138839
our results indicate that down-regulation of UBC9 sensitizes cells to anticancer drugs, is possibly associated with the regulation of ERK1/2 and P38 activation and interacts with the intrinsic apoptosis pathway. PMID: 28572537
Ubc9 is an essential regulator of ADAP where it is required for TCR-induced membrane recruitment of the small GTPase Rap1 and its effector protein RapL and for activation of the small GTPase Rac1 in T cell adhesion. PMID: 29127148
NUSAP1 contributes to accurate chromosome segregation by acting as a co-factor for RanBP2-RanGAP1-UBC9 during cell division. PMID: 28900032
Listeriolysin O -induced down-regulation of Ubc9 is independent of Ubc9-SUMO interaction, however, it may involve phosphorylation signaling. PMID: 28911869
Sumoylation of PML with SUMO2 by UBC9/UBE2I can lead to formation of polymeric SUMO chains. Data suggest that coordination of growing poly-SUMO chain with "back side" binding site on UBC9/UBE2I appears to be required for SUMO chain elongation on PML. (PML = promyelocytic leukemia protein; SUMO2 = small ubiquitin-like modifier 2; UBC9/UBE2I = ubiquitin-conjugating enzyme UBC9/UBE2I) PMID: 28784659
The role of Transthyretin in the regulation of Ubc9 SUMOylation PMID: 27501389
These findings point to UBC9 and autophagy as novel hallmarks of human papillomavirus oncogenesis PMID: 28253371
These findings reveal that SUMO E1~E2 oxidation is an essential redox switch in oxidative stress. PMID: 27174643
the mRNA and protein expression of Ubc9 are regulated by the microRNA miRNA-30a (miR-30a) in human subcutaneous adipocytes. PMID: 27758866
miR-30e in VSMCs exerted an anti-atherosclerosis effect via inhibiting proliferation and migration, and promoting apoptosis of VSMCs. More specifically, it was demonstrated that miR-30e exhibited these effects on VSMCs partially through targeting Ube2i and downregulating the IkappaBalpha/NFkappaB signaling pathway. PMID: 28123167
Ubc9 plays different roles of action in antitumor agents in chemotherapy. The process requires bleomycin hydrolase and poly(ADP-ribose) polymerase-1. The results are beneficial to deeply understanding of Ubc9 functions and for precise prediction of chemotherapy outcomes in tumors. PMID: 27878232
Suggest a novel role of PCGF2 in arsenic trioxide-mediated degradation of PML-RARA that PCGF2 might act as a negative regulator of UBE2I via direct interaction. PMID: 27030546
Akt directly phosphorylates Ubc9 at Thr35 and phosphorylates SUMO1 at Thr76. Ubc9 phosphorylation at Thr35 promotes Ubc9 thioester bond formation and SUMO1 phosphorylation at Thr76 stabilizes the SUMO1 protein. PMID: 25867063
Characterization and Structural Insights into Selective E1-E2 Interactions in the Human and Plasmodium falciparum SUMO Conjugation Systems. PMID: 26697886
a high-throughput microscopy screen identified ubiquitin carrier protein 9 (Ubc9) as a negative regulator of energy storage in human sc adipocytes. Ubc9 depletion enhanced energy storage and induced the brown fat gene program in human sc adipocytes. PMID: 26192107
The authors show that ZNF451 is SUMO2 specific and that SUMO modification of ZNF451 may contribute to activity by providing a second molecule of SUMO that interacts with E2. PMID: 26524494
The RWD domain binds to a Ubc9 surface that also must interact with E1, E3, and SUMO. PMID: 25918163
These data show that NS5A is a target protein of small ubiquitin-like modifier (SUMO) and is SUMOylated at lysine residue 348 and silencing of UBC9 impaired hepatitis C virus replication. PMID: 24602294
SUMO E2 ligase Ubc9 has a critical role in oncogenesis driven by the Ras/Raf pathway PMID: 25805818
Ubc9 gene plays an important role in cell proliferation in epithelial ovarian cancer through PI3K/Akt signaling pathway. PMID: 23708104
Data indicate that protein tyrosine phosphatase 1B (PTP1B) association with calnexin is ubiquitin conjugating enzyme 9 (UBC9)-dependent. PMID: 25586181
N-terminal amino acid residues of Ubc9 are critical for Ubc9 nuclear enrichment and localization. PMID: 25637535
the Ran system and Ubc9 are functionally coupled to the structure of the nuclear lamina and reactive oxygen species production through feedback loops PMID: 24523287
Although E2 approximately SUMO-1 exhibits no specificity for product-bound TDG, the relatively high conjugation efficiency raises the possibility that E2-mediated sumoylation could stimulate product release in vivo. PMID: 24753249
The variability of the UBC9 gene can play a role in breast cancer occurrence. PMID: 23873416
UBC9 appears to play an important role in the tumor biology of Nigerian women. PMID: 24176171
miR-214 and its target gene UBC9 may contribute to the development and the clinical outcome of glioma PMID: 24277415
The proximal UBC9 promoter. PMID: 24086615
Study showed that ZHX1 is SUMOylated by Ubc9 with SUMO1 at the sites K159, K454, and K626 and that the SUMOylation of ZHX1 regulated the stability, ubiquitination and transcriptional activity of ZHX1. PMID: 23686912
This study provides further insight in the processing and packaging of the HIV-1 gp120 into mature HIV-1 virions. PMID: 23861967
We observed steady-state expression of SUMO-conjugated enzyme-UBC9 throughout normal gestation. Placental UBC9 levels were strikingly increased in severe pre-eclampsia patients. PMID: 23628505
These results suggest that the SUMOylation of DDB2 facilitates CPD repair. PMID: 23860269
we demonstrated that upregulation of Ubc9 expression promotes migration and invasion. Ubc9 likely plays an important role in cancer progression by promoting invasion and metastasis in lung cancer. PMID: 23381475
High UBC9 expression is associated with glioma. PMID: 23187003
From these observations, we concluded that UBC9 is a novel regulator of the mammalian ER stress response. PMID: 23470653
The E2 enzyme Ubc9 is an interaction partner of E1B-55K, providing a possible molecular explanation for SUMO-dependent modulation of cellular target proteins. PMID: 22614022
A previously undescribed SIRT1/Ubc9 regulatory axis in the modulation of protein sumoylation and the hypoxia response. PMID: 23395904
High Ubc9 expression correlates with poor response to chemotherapy and poor clinical prognosis in breast cancer. PMID: 21880185
Data show that the SAE2 subunit of the small ubiquitin-like modifier (SUMO) E1 is autoSUMOylated at residue Lys-236, and SUMOylation was catalyzed by Ubc9 at several additional Lys residues surrounding the catalytic Cys-173 of SAE2. PMID: 22403398
UBC9 protein expression is reduced in muscle from type 2 diabetic patients with severe insulin resistance. PMID: 22114711
There was no statistical association of UBE2I expression between human epithelial ovarian cancer tumor and normal tissues PMID: 21971700
Ubc9 and PIAS1 potentiated SF-1-mediated transactivation of human CYP17, CYP11A1, and CYP11B1 but not CYP11B2 promoters. PMID: 21467194
Binding of BRCA1 proteins to nuclear chaperone Ubc9 provides a novel mechanism for nuclear import and control of tumor growth. PMID: 21344391
The authors propose that LMP1, by interaction with Ubc9, modulates sumoylation processes, which regulate signal transduction pathways that affect phenotypic changes associated with oncogenesis. PMID: 21795333
The authors report that the high risk human papillomavirus E6 proteins reduce the intracellular quantity of the sole SUMO conjugation enzyme, Ubc9, concomitant with decreased host sumoylation. PMID: 21510985
Analysis of the dynamics of E2(Ubc9)-SUMO-Target(RanGAP1) in the absence and presence of E3(RanBP2) revealed that two different allosteric sites regulate the ligase activity. PMID: 21216249

Hide All

Subcellular Location

Nucleus. Cytoplasm.

Protein Families

Ubiquitin-conjugating enzyme family

Tissue Specificity

Expressed in heart, skeletal muscle, pancreas, kidney, liver, lung, placenta and brain. Also expressed in testis and thymus.

Database Links

HGNC: 12485

OMIM: 601661

KEGG: hsa:7329

STRING: 9606.ENSP00000324897

UniGene: Hs.302903

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA032018A0HU
Size	US$210
	Order now
Image	Western Blot Positive WB detected in: A549 whole cell lysate(30µg), HeLa whole cell lysate(30µg), HepG2 whole cell lysate(30µg), HEK293 whole cell lysate(30µg), K562 whole cell lysate(30µg), SH-SY5Y whole cell lysate(30µg), NIH/3T3 whole cell lysate(30µg) All lanes: UBE2I antibody at 1:1000 Secondary Goat polyclonal to rabbit IgG at 1/50000 dilution Predicted band size: 18 kDa Observed band size: 18 kDa Exposure time: 3min Overlay Peak curve showing jurkat cells stained with CSB-RA032018A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/110⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/110⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions?	Leave a Message or Start an on-line Chat

UBE2I Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background